, Volume 38, Issue 1, pp 47–51 | Cite as

Increasing Occurrence of Multidrug-Resistance in Acinetobacter baumannii Isolates From Four German University Hospitals, 2002–2006

  • M. WadlEmail author
  • K. Heckenbach
  • I. Noll
  • S. Ziesing
  • W. Pfister
  • J. Beer
  • S. Schubert
  • T. Eckmanns
Clinical and Epidemiological Study



Acinetobacter baumannii can cause severeinfections, mainly in critically ill inpatients. Treatment iscomplicated by multidrug-resistance (MDR). In Germany, todate, little is known on the extent of MDR in A. baumanniiisolated from inpatients in German hospitals and potentialfactors influencing the emergence of MDR.

Materials and Methods:

We retrospectively analysed thedata of A. baumannii isolates from the inpatients of fourGerman university hospitals, tested for antimicrobial resistancewith the broth dilution method between 2002 and2006. We defined MDR as resistance to three or more classesof recommended drugs. After calculating the proportions ofMDR in A. baumannii isolates, we investigated the associationbetween MDR in A. baumannii and year of pathogenisolation, hospital, ward type, specimen and demographics.We performed descriptive analysis and multivariable logisticregression. Additionally, proportions of in vitro drug effectivenessagainst multidrug-resistant and non-multidrugresistantA. baumannii isolates were determined.


MDR was found in 66 of 1,190 (5.6%)A. baumannii isolates and increased from 2.1% in 2002 to7.9% in 2006. The highest proportions of MDR were foundin hospital A (8.9%), in intensive care units (7.3%), inisolates from blood (7.6%) and in male patients aged60 years or older (6.6%). In multivariable analysis, thechance of MDR in A. baumannii isolates increased with thesuccessive years of pathogen isolation (odds ratio [OR] 1.3,95% confidence interval [CI] 1.1–1.5) and there was ahigher risk of MDR in A. baumannii in intensive care units(OR 1.8, 95% CI 1.1–2.9). The lowest in vitro antibioticresistance was found in meropenem, imipenem and ampicillin/sulbactam, with 33, 37 and 39% for multidrugresistantand 0.4, 1 and 3% in non-multidrug-resistantA. baumannii isolates, respectively.


The increase of MDR in A. baumannii isolatesfrom 2002 to 2006 in four hospitals suggests that cliniciansin Germany may expect a rising proportion of MDR inA. baumannii isolates among inpatients. The antimicrobialsusceptibility testing of A. baumannii isolates against recommendeddrugs, combined with in-house antimicrobial resistancesurveillance, is needed to ensure appropriate treatment.


Imipenem Meropenem Acinetobacter Tigecycline Acinetobacter Baumannii 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bergogne-Bérézin E, Towner KJ: Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9: 148–165.PubMedGoogle Scholar
  2. 2.
    Munoz-Price LS, Weinstein RA: Acinetobacter infection. N Engl J Med 2008; 358: 1271–1281.CrossRefPubMedGoogle Scholar
  3. 3.
    Falagas ME, Bliziotis IA, Siempos II: Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006; 10: R48.CrossRefPubMedGoogle Scholar
  4. 4.
    Paul M, Weinberger M, Siegman-Igra Y, Lazarovitch T, Ostfeld I, Boldur I, Samra Z, Shula H, Carmeli Y, Rubinovitch B, Pitlik S: Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997–2002. J Hosp Infect 2005; 60: 256–260.CrossRefPubMedGoogle Scholar
  5. 5.
    Kramer A, Schwebke I, Kampf G: How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis 2006; 6: 130.CrossRefPubMedGoogle Scholar
  6. 6.
    Wendt C, Dietze B, Dietz E, Rüden H: Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 1997; 35: 1394–1397.PubMedGoogle Scholar
  7. 7.
    Dijkshoorn L, Nemec A, Seifert H: An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5: 939–951.CrossRefPubMedGoogle Scholar
  8. 8.
    Turner PJ, Greenhalgh JM: The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997–2000. Clin Microbiol Infect 2003; 9: 563–567.CrossRefPubMedGoogle Scholar
  9. 9.
    Halstead DC, Abid J, Dowzicky MJ: Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007; 55: 49–57.CrossRefPubMedGoogle Scholar
  10. 10.
    Anonymous: Deutsches Institut für Normung e. V. Medizinische Mikrobiologie: Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika - teil 4: Bewertungsstufen für die minimale Hemmkonzentration - Mhkgrenzwerte von antibakteriellen Wirkstoffen. Berlin: Beuth Verlag 2004; DIN 58940-4, Bbl 1.Google Scholar
  11. 11.
    Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538–582.CrossRefPubMedGoogle Scholar
  12. 12.
    Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A: Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007; 13: 97–103.CrossRefPubMedGoogle Scholar
  13. 13.
    Karageorgopoulos DE, Falagas ME: Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008; 8: 751–762.CrossRefPubMedGoogle Scholar
  14. 14.
    Urban C, Segal-Maurer S, Rahal JJ: Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003; 36: 1268–1274.CrossRefPubMedGoogle Scholar
  15. 15.
    Anonymous: Act on the Reform of the Communicable Diseases Law (Communicable Diseases Law Reform Act). 2000. Available online at:,template Id=raw,property=publicationFile.pdf/inf_dis_down.pdf.

Copyright information

© Urban & Vogel 2010

Authors and Affiliations

  • M. Wadl
    • 1
    Email author
  • K. Heckenbach
    • 2
  • I. Noll
    • 2
  • S. Ziesing
    • 3
  • W. Pfister
    • 4
  • J. Beer
    • 5
  • S. Schubert
    • 6
  • T. Eckmanns
    • 2
  1. 1.Postgraduate Training for Applied Epidemiology (PAE, German FieldEpidemiology Training Programme)Dept. for Infectious DiseaseEpidemiology, Robert Koch-InstituteBerlinGermany
  2. 2.Dept. for Infectious Disease EpidemiologyRobert Koch-InstituteBerlinGermany
  3. 3.Institute for Medical Microbiology and Hospital EpidemiologyHannoverMedical SchoolHannoverGermany
  4. 4.Institute of Medical MicrobiologyFriedrich-Schiller-UniversityJenaGermany
  5. 5.Institute for Medical Microbiology and Epidemiology of InfectiousDiseasesUniversity of LeipzigLeipzigGermany
  6. 6.Institute for Infection MedicineUniversity Medical Center Schleswig-Holstein Campus KielKielGermany

Personalised recommendations